BrainChip & Biotome - Govt Funding for neutralising antibodies SARS- CoV-2 infection, page-2

BrainChip andBiotome partner to develop SARS-CoV-2 antibody tests

Australia-based BrainChip Research Institute and Biotome have enteredinto a research partnership to develop antibody tests for infections such asSARS-CoV-2.The Akida processor has the ability to learn newsensory data patterns rapidly and categorise the results in milliseconds whileconsuming just microwatts of power. Credit: Marco Verch ProfessionalPhotographer on Flickr.

Australia-based BrainChip Research Institute andBiotome have entered into a research partnership to develop antibody tests forinfections such as SARS-CoV-2.

BrainChip’s Akida neuromorphic processor chip willbe used to infer sensor responses and to analyse which responses are mostrepresentative for protective antibodies.

The research project is aimed at designing ahandheld device that will deliver precise results in seconds by usingnanomaterial-based sensors and the Akida chip.

Biotome CEO Dr Samuel Lundin said: “Our partnershipwith BrainChip is an important step for our development of point-of-care teststhat are based on patented high-precision immunological markers.

“The joint project we are embarking on aims to useAkida to identify the antibodies that can protect against SARS-CoV-2 infection– the so-called neutralising antibodies.”

The Akida processor has a major role in the developmentdue to its ability to learn new sensory data patterns rapidly and categorisethe results in milliseconds while consuming just microwatts of power.